Cambridge, MA-based Bluebird Bio (NASDAQ: BLUE) has named Susanna High, formerly of Alnylam Pharmaceuticals and Millennium Pharmaceuticals, its chief operating officer. Andrew Obenshain, a veteran of Shire and Genzyme before that, will lead Bluebird’s operations in Europe.
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
From Our Editors · Podcast
The AI, Big Data, and R&D Boom
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
